COMMUNIQUÉS West-GlobeNewswire

4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
12/11/2026
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, [...]
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus Initiated Phase 2 studies with [...]
LifeMD Reports Third Quarter 2026 Results
12/11/2026
Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million. Adjusted EBITDA improved approximately [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
12/11/2026
PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
12/11/2026
The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the [...]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
12/11/2026
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical [...]
Solésence Reports Record Third Quarter 2026 Financial Results
12/11/2026
Third quarter revenue increases 38% year-over-year to $20.2 million Third quarter net income of $3.7 million highest in company’s history Company to host conference call today at 4:00 p.m. CT, 5:00 p.m. ET ROMEOVILLE, [...]
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
12/11/2026
– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response [...]
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
12/11/2026
Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the first half of 2027 LOS ANGELES, Nov. 12, 2026 ( [...]
Jushi Holdings Inc. Announces Opening of Relocated Beyond Hello™ Dispensary in Hamburg, Pennsylvania
12/11/2026
BOCA RATON, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ) , a vertically integrated, multi-state cannabis operator, today announced the opening of [...]
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
12/11/2026
On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up [...]
Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)
12/11/2026
FORT WORTH, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and [...]
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
12/11/2026
Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at [...]
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12/11/2026
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on [...]
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
12/11/2026
— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement — — Interim NEXICART-2 clinical [...]
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
12/11/2026
Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth Jemperli approved in the U.S. as the first and only immunotherapy for adults [...]
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12/11/2026
KUALA LUMPUR, MALAYSIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/11/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 nov. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
12/11/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE [...]

Pages